Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target

Rigel Pharmaceuticals is supported by a diversified commercial portfolio and a strengthening oncology franchise, with Gavreto showing clinically meaningful activity across RET fusion-positive solid tumors, including a 53% overall response rate in pooled analysis, 81.3% in thyroid cancer, and 65.5% versus 41.6% in first-line NSCLC versus standard of care. Rezlidhia also adds to the bull case, as long-term responder data showed durable benefit with 48-month estimated OS of 74% and EFS of 69%, while real-world datasets reinforce its role after venetoclax failure in R/R mIDH1 AML. The launch of Veppanu further broadens the growth base, and the cited sum-of-the-parts framework values Rigel’s commercial assets at $81.90 per share, reflecting continued revenue growth from Tavalisse and Rezlidhia and additional upside from R289.

Rigel Pharmaceuticals is exposed to significant clinical and commercial risk because its pralsetinib data show higher grade ≥3 infections and 8 fatal infection events versus none with standard of care, undermining confidence in the drug’s safety profile. Although responses were more durable, with median duration of response of 20.6 months versus 9.7 months and p = 0.0043, there was no significant overall survival difference at the time of analysis, and the endpoint remained immature with at least 70% of patients in each arm alive. The crossover of 38 standard-of-care patients to pralsetinib also complicates interpretation, while the olutasidenib real-world evidence, though supportive after venetoclax failure, is limited to publication-only ASCO abstracts and does not offset the safety concerns.